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Summary
Fluorochrome-conjugated peptide–major histocompatibility complex
(pMHC) multimers are widely used for flow cytometric visualization of
antigen-specific T cells. The most common multimers, streptavidin–biotin-
based ‘tetramers’, can be manufactured readily in the laboratory. Unfortu-
nately, there are large differences between the threshold of T cell receptor
(TCR) affinity required to capture pMHC tetramers from solution and that
which is required for T cell activation. This disparity means that tetramers
sometimes fail to stain antigen-specific T cells within a sample, an issue that
is particularly problematic when staining tumour-specific, autoimmune or
MHC class II-restricted T cells, which often display TCRs of low affinity
for pMHC. Here, we compared optimized staining with tetramers and
dextramers (dextran-based multimers), with the latter carrying greater
numbers of both pMHC and fluorochrome per molecule. Most notably, we
find that: (i) dextramers stain more brightly than tetramers; (ii) dextramers
outperform tetramers when TCR–pMHC affinity is low; (iii) dextramers out-
perform tetramers with pMHC class II reagents where there is an absence of
co-receptor stabilization; and (iv) dextramer sensitivity is enhanced further
by specific protein kinase inhibition. Dextramers are compatible with
current state-of-the-art flow cytometry platforms and will probably find par-
ticular utility in the fields of autoimmunity and cancer immunology.
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Introduction
The use of fluorochrome-conjugated peptide–major histo-
compatibility complex (pMHC) multimers in conjunction
with flow cytometry has become commonplace methodol-
ogy for studying antigen-specific T cell populations [1,2].
pMHC multimers offer several advantages over other tech-
nologies for the identification of antigen-specific T cells, as
they can detect T cells regardless of their effector function
and without the requirement for cellular activation. This
feature enables phenotyping of T cells directly ex vivo by
using a spectrum of fluorochrome-conjugated antibodies
specific for other T cell markers. More recent advances have
expanded possibilities by using heavy atom-conjugated
pMHC multimers and antibodies in combination with mass
spectrometry [3]. The success of pMHC multimers is dem-
onstrated by their use in thousands of published studies
and the commercialization of several different pMHC
multimerization platforms [1]. The original such platform,
an avidin–biotin-based tetramer [4], is still the most
common format in use, as it can be readily manufactured in
laboratories equipped with basic protein expression and
purification facilities. However, several other multimeri-
zation strategies are now available to investigators,
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including pMHC pentamers and octamers [1]. Dextran-
based pMHC multimers (dextramers) are a more recent
addition to this toolbox [5].
We have determined previously that the binding affinity
threshold for pMHC class I (pMHC-I) tetramers is signifi-
cantly higher than that required for T cell activation [6]. As
a result, pMHC-I tetramers can often fail to stain antigen-
specific T cells where the interaction between pMHC and T
cell receptor (TCR) is weaker than KD = 80 μM. Such weak
TCR–pMHC affinities are not usually characteristic of
CD8+ T cells specific for foreign, pathogen-derived antigens,
and pMHC-I tetramers have excelled when used to charac-
terize virus-specific cytotoxic T lymphocyte (CTL) popula-
tions. In contrast, the use of pMHC-I tetramers can be
more problematic when the reagents are used to identify T
cells specific for self-derived peptides (anti-tumour and
autoimmune T cells). Self-reactive T cells are known to gen-
erally bear weaker binding TCRs [7]. This is thought to be
the result of thymic editing that culls T cells bearing higher-
affinity self-reactive TCRs [7]. Thus, at present, pMHC-I
tetramers cannot be used to detect all antigen-specific CD8+
T cells [1,6]. There are further issues with the use of pMHC
class II (pMHC-II) tetramers for the detection of T helper
cells [1,8]. First, antigen-specific CD4+ T cell populations
tend to be considerably smaller in number than the larger
anti-viral CD8+ T cell populations. Secondly, MHC-II-
restricted TCRs bind with approximately fivefold lower
affinity than MHC-I-restricted TCRs [7]. Thirdly, while the
CD8 molecule stabilizes TCR–pMHC-I interactions
through effects on both the TCR on-rate and off-rate, the
CD4 co-receptor does not contribute to TCR–pMHC-II
binding [1,9–15]. The lower affinity of TCR–pMHC-II
interactions combines with the lack of CD4 ‘co-receptor
help’ to ensure that the average CD4+ T cell is almost
50-fold more difficult to stain with pMHC tetramers than
the average CD8+ T cell [1]. Thus, there is a currently a
pressing need to extend pMHC multimer technology to a
point where it can be used to stain all antigen-specific T
cells in all biological systems. This requirement is greatest
for MHC-II-restricted T cells and most T cells that target
self-derived peptides [16].
Several improvements of pMHC multimer technology
can be used to extend the range of TCR–pMHC interac-
tions that are amenable to detection. The use of higher con-
centrations of pMHC multimer can, to some extent, aid
staining where TCR–pMHC interactions are weak [1].
However, such use is not economically attractive and can
result in concomitant increases in background staining. It is
also established that anti-co-receptor antibodies can regu-
late pMHC multimer binding [1,11,13,14,17]. In general,
researchers now stain with pMHC multimer prior to
co-receptor staining. It has also been established that some
murine and human anti-CD8 antibodies act to enhance the
capture of pMHC-I multimer from solution, so the use of
anti-co-receptor antibodies that enhance pMHC multimer
staining is recommended [18]. It is possible to further
increase the range of TCR–pMHC interactions that are
amenable to pMHC-I tetramer staining by using CD8-
enhanced tetramers [13]. However, enhancing the universal
pMHC-I–CD8 interaction could potentially result in an
artificial increase in the degeneracy of TCR binding [12].
The more recent procedure of including a non-toxic, revers-
ible protein kinase inhibitor (PKI) during pMHC multimer
staining can also increase the range of TCR–pMHC interac-
tions that can be detected with pMHC multimers without
altering the TCR–pMHC or pMHC–CD8 interactions [19].
This simple technology can result in >50-fold improve-
ments in the staining of T cells bearing very weak binding
TCRs, and is universally applicable to pMHC multimer
staining of CD8+ and CD4+ human, other primate or
murine T cells [1,19].
To address these evident technology gaps, we have evalu-
ated the use of pMHC-I and pMHC-II tetramers and
dextramers across a range of systems. Specifically, we aimed
to examine whether pMHC dextramers could be used to
stain T cells with a low TCR–pMHC affinity and whether
this novel technology was preferable to classical pMHC
tetramers for the detection of tumour-specific, autoimmune
and pMHC-II-restricted T cell populations that tend to
display weaker affinity TCRs and are undetectable by con-
ventional means.
Materials and methods
Cells and cell lines
The following human leucocyte antigen (HLA)-A*0201
(HLA-A2)-restricted CD8+ T cell clones were used: (i) ILA1,
which recognizes the ILAKFLHWL epitope from human
telomerase reverse transcriptase (hTERT: residues 540–548)
[20], in addition to four altered peptide ligands (APL) to
which the ILA1 TCR has varying affinities [21]; (ii)
NLV2F3, which recognizes the NLVPMVATV epitope from
cytomegalovirus (CMV) pp65 (residues 495–503); and (iii)
3F2 and 1E6, which recognize the ALWGPDPAAA epitope
from preproinsulin (PPI: residues 15–24) and originate
from a patient with type 1 diabetes (T1D) [22,23]. The
HLA-A*2402 (HLA-A24)-restricted clone, 4C6, was also
generated from a patient with T1D and recognizes the
LWMRLLPLL epitope from PPI (residues 3–11) [24].
Additionally, the HLA-DRB1*0101 (HLA-DR1)-restricted
CD4+ clone, Flu2C5, was used, which recognizes the
PKYVKQNTLKLAT epitope from influenza A haemaggluti-
nin (HA: residues 307–319) [25]. T cell clones were rou-
tinely expanded by restimulation with allogeneic peripheral
blood mononuclear cells (PBMCs) and phytohaemag-
glutinin (PHA), as described previously [26], then cultured
for at least 2–3 weeks before being used for experimenta-
tion. Fresh heparinized blood was obtained from volunteers
or via the Welsh Blood Service, with appropriate ethical
G. Dolton et al.
48 © 2014 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 177: 47–63
approval. PBMCs were isolated by standard density cen-
trifugation, by layering blood over an equal volume of
lymphoprep (Axis Shields, Dundee, UK). PBMCs were
either used immediately or from cryopreserved samples,
with the latter being treated with 10–50 μg/ml of DNase I
(Roche, Burgess Hill, UK) for 30 min at 37°C after thawing.
Spiked samples were created by mixing clonal T cells (104)
with PBMCs (106). The spiked PBMCs were minimally
HLA-matched for the restricting HLA of the spiking clone.
Tetramer and dextramer assembly
Soluble biotinylated pMHC-I and pMHC-II monomers
were produced as described previously [15], with the same
monomeric pMHC protein being used to make paired
tetramers and dextramers for direct comparison. Tetramers
were assembled by the stepwise addition of R-phycoerythrin
(PE), allophycocyanin (APC) or Alexa Fluor 488
(Alexa488)-conjugated streptavidin (all from Life Technolo-
gies, Paisley, UK) at a molar pMHC : streptavidin ratio of
4:1. Dextran–streptavidin–fluorochrome conjugates were
provided by Immudex Limited (Copenhagen, Denmark)
and consist of a dextran polymer scaffold with covalently
linked fluorochrome and streptavidin. Individual
dextramers conjugated to PE, APC and fluorescein
isothiocyanate (FITC) averaged 3, 7 and 33 fluorochrome
molecules and typically, 6, 3 and 13 streptavidins with the
typical number of streptavidins per dextramer exhibiting
the expected Gaussian distribution. The amount of input
streptavidin was determined by absorbance at 280 nm. After
reaction with the dextran backbone and purification, the
amount of streptavidin in the dextran-conjugate and
‘supernatant’ (free streptavidin) was measured by absorb-
ance at 280 nm and used to calculate the number of
strepavidin molecules per dextran molecule for each batch
of dextramer ‘backbone’. Dextramers (dextramer backbone
and pMHC) were assembled by the addition of monomeric
pMHC at a molar ratio of 3:1 (APC and PE) or 1:1 (FITC),
with respect to the streptavidin component of the
dextramer backbone, for 30 min at room temperature.
Once assembled, tetramer and dextramer were standardized
to a working concentration of 0·1 mg/ml in phosphate-
buffered saline (PBS) or dextramer buffer (0·05 M Tris-
HCL, 15 mM NaN3, 1% bovine serum albumin, pH 7·2)
filtered at 0·2 μm, respectively. Protease inhibitors (Set 1;
Merck, London, UK) were then added and the reagents
stored at 4°C in the dark.
Cell staining and flow cytometry
All tetramers, dextramers and monoclonal antibodies con-
jugated to either quantum-dot (QD) 705 or APC-H7 were
microcentrifuged for 1 min before use to remove aggre-
gates. A total of 5–10 × 104 of a T cell clone or 2–4 × 106 of
PBMCs (spiked or unspiked) were stained with a desired
amount of tetramer (range between 1·25–40 μg/ml with
respect to the pMHC component) or dextramer (range
between 0·74–24 μg/ml with respect to the pMHC compo-
nent) in 50 μl of staining buffer [PBS supplemented with
2% fetal bovine serum (FBS) or 1% human serum and
25 mM HEPES buffer]. Routine stains were performed
using 0·5 μg of tetramer (10 μg/ml) or 0·3 μg of dextramer
(6 μg/ml) per sample for 30 min on ice to ensure optimal
discrimination (Fig. 1 and Supporting Information Fig. S1).
All cell samples were subsequently stained with a LIVE/
DEAD amine-reactive dye (Violet or Aqua; Life Technolo-
gies) for 5 min at room temperature. In some instances,
clonal T cells were stained further with anti-CD4 (αCD4)
(VIT4; Miltenyi Biotec, Bergisch Gladbach, Germany; SK3,
BD Biosciences) or αCD8 (BW135/80, Miltenyi Biotec; SK1,
BD Biosciences, Oxford, UK) antibodies for 20 min on ice.
PBMCs (spiked or unspiked) were stained further with
αCD14 (M5E2; BioLegend, London, UK), αCD19 (H1B19,
BioLegend), αCD3 (BW264/56, Miltenyi Biotec; SK3, BD
Biosciences) and/or αCD4/αCD8 antibodies for 20 min on
ice. For immunophenotyping experiments, PBMCs
prelabelled with tetramer or dextramer were stained with
LIVE/DEAD Violet (ViViD; Life Technologies) as above and
a panel of directly conjugated monoclonal antibodies as
follows: (i) αCD14 Pacific Blue (TüK4), αCD19 Pacific Blue
(SJ25-C1), αCD8 QD705 (3B5) and αCD69 APC (CH/4)
(Life Technologies); (ii) αCD3 APC-H7 (SK7), αCD57
FITC (NK-1) and αCCR7 PE-Cy7 (3D12) (BD
Biosciences); and (iii) αCD27 PE-Cy5 (1A4CD27) and
αCD45RO ECD (UCHL1) (Beckman Coulter, High
Wycombe, UK). Typically, PBMC samples were gated seri-
ally on single, amine/CD14/CD19 (dump)-negative, CD3+
lymphocytes and displayed in bivariate tetramer/dextramer
versus CD4/CD8 plots. Data were acquired using either
a FACSCanto II or a customized FACSAria II (BD
Biosciences) and analysed with FlowJo software (TreeStar
Inc., Ashland, OR, USA).
Protein kinase inhibitor treatment
The PKI, dasatinib (Axon Medchem, Reston, VA, USA), was
used at a final concentration of 50 nM [19]. Briefly, 1 mM
dimethylsulphoxide (DMSO) aliquots of PKI were stored at
−20°C. Working aliquots of 100 nM were prepared in PBS
and, for each sample, an equal volume was added to 25 μl of
cells in staining buffer. The cells were then incubated at
37°C in a sealed tube for 30–60 min, after which tetramer or
dextramer was added and incubated as described. Of note,
we have found that dasatinib stocks are labile when stored
at 4°C and therefore recommend storing as one-use frozen
aliquots. The effectiveness of the reagent can be tested by
confirming an increase in surface expression of TCR and
co-receptor on the T cell surface after extended incubations
[1].
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Fig. 1. Peptide–major histocompatibility complex (pMHC) dextramers bind CD8+ T cells substantially better than tetramers when T cell receptor
(TCR)–pMHC affinity is low. (a) A schematic showing how pMHC dextramers differ from pMHC tetramers. Dextramers have a dextran backbone and
carry more fluorochrome and pMHC per molecule. The fluorochrome/pMHC ratio differs between allophycocyanin (APC) and R-phycoerythrin (PE)
dextramers. Figure 1(a) is available as a separate high-resolution file (Supporting Information Fig. S3) in the online supplement that accompanies this
article. (b) The ILA1 CD8+ T cell clone was stained with PE-conjugated tetramer (right) or dextramer (left) reagents constructed with human leucocyte
antigen (HLA)-A2 monomers bearing the wild-type human telomerase reverse transcriptase (hTERT)540–548 peptide (ILAKFLHWL), variants thereof
with defined TCR–pMHC-I affinities as indicated, or the HIV-1 Pol476–484 peptide (ILKEPVHGV) as an irrelevant control. (c) Human peripheral blood
mononuclear cells (PBMCs) (106) were spiked with clonal ILA1 cells (104) and stained with the indicated tetramers (bottom) or dextramers (top), the
viability dye Aqua and monoclonal antibodies against the surface markers CD3, CD4, CD8, CD14 and CD19. Gates were set serially on lymphocytes,
single cells and live CD3+CD14−CD19− cells prior to display as CD8 versus tetramer/dextramer. In each column, the red box is positioned on the
antigen-specific CD8+ T cell population that stains most brightly to aid visual comparison.
G. Dolton et al.
50 © 2014 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 177: 47–63
Intracellular cytokine staining
Prior to activation, cells were washed from culture medium
and incubated for 24 h in ‘resting’ media (RPMI supple-
mented with 5% FBS, L-glutamine and antibiotics). For
activation, cells were incubated at 37°C for 5 h with cognate
peptide in 200 μl (3 × 106 cells per ml, 96 round-bottomed
culture plates) of resting media containing GolgiStopTM and
GolgiPlugTM (both BD Biosciences), according to the manu-
facturer’s instructions. Cells were subsequently stained with
a viability dye, equimolar amounts of cognate or irrelevant
dextramer and tetramer (6 μg/ml with respect to the
pMHC component), and antibodies against cell surface
markers (CD8, CD19, CD14 and CD3) as described above
for the staining of PBMCs. Cells were prepared for intracel-
lular cytokine staining by incubation with Cytofix/
CytopermTM (BD Biosciences) according to the manufac-
turer’s instructions (including wash steps), followed by
20 min on ice with mouse αhuman interferon (IFN)-γ anti-
body (45-15; Miltenyi Biotec). Cells were stored overnight
(4°C in the dark) and flow cytometry and data analysis per-
formed as above.
Fluorescent microscopy
A total of 105 CD8+ T cells were labelled with
4′,6-diamidino-2-phenylindole (DAPI) nuclear stain (Life
Technologies) and either Alexa488-conjugated peptide-
MHC tetramers (at a final concentration of 12·5 μg/ml) or
FITC-conjugated dextramers (at a final concentration of
16·25 μg/ml) for 30 min at 37°C or on ice. After three
washes with PBS, each sample was fixed in 2% paraformal-
dehyde. After fixing, the CD8+ T cells were resuspended in
100 μl of 2% FBS/PBS and then spun onto microscope
slides at 34 × g for 5 min using a CytoSpin III centrifuge
(Harlow Scientific, Arlington, MA, USA). Samples were
observed using a Leica DM LB2 (Leica Microsystems,
Milton Keynes, UK) fluorescence microscope.
Results
Optimized T cell staining with pMHC tetramers
and dextramers
We aimed to compare the staining of antigen-specific T cells
with pMHC tetramers and dextramers. The dextran back-
bone of pMHC dextramers means that these reagents can
carry a higher number of pMHC and fluorochrome per
molecule than pMHC tetramers (Fig. 1a). We first set out to
establish the optimal staining conditions for pMHC
tetramers and dextramers so that we could compare the
optimal detection parameters of each reagent. For this
purpose we made use of the ILA1 CD8+ T cell clone that
recognizes the HLA-A2 restricted ILAKFLHWL epitope
from hTERT (residues 540–548). The hTERT epitope is not
naturally presented at the tumour cell surface [20], and
therefore constitutes a model system that is uncomplicated
by the possibility of a natural ligand. Furthermore, we have
previously characterized biophysically a wide range of APL
for this TCR that range in affinity from KD ∼3 μM to KD
∼2 mM [6,21]. This controllable system allows the TCR–
pMHC affinity to be varied while other variables such as
surface density of TCR and CD8 remain identical. We pre-
pared stocks of HLA-A2–ILAKFLHWL and APL variants
thereof, and the human immunodeficiency (HIV)-1 Pol
epitope, ILKEPVHGV (residues 476–484), as a non-cognate
control. These preparations were used to generate tetramers
and dextramers conjugated to the PE fluorochrome. The
cognate ILA1 T cell clone was stained with HLA-A2–
ILAKFLHWL and HLA-A2–ILKEPVHGV control reagents
over a range of pMHC concentrations in order to establish
the optimal signal-to-noise ratio for each reagent. A titra-
tion of dextramer preparation from 0·037 to 1·2 μg (0·74–
24 μg/ml) per test, with respect to the pMHC component,
per test, established that 0·3 μg (6 μg/ml) gave the best
signal-to-noise ratio (Supporting Information Fig. S1a,b).
For tetramer, the optimal signal-to-noise ratio was seen
when using 0·5 μg (10 μg/ml) of tetramer per test, with
respect to pMHC (Supporting Information Fig. S1c,d).
Thus, optimal staining with pMHC tetramers required 1·6-
fold more pMHC compared with optimal staining with
dextramers. Additionally, the mean fluorescence intensity
(MFI) achieved with optimal dextramer staining was more
than fourfold greater than could be achieved with tetramer
(Supporting Information Fig. S1c). This most probaby
reflects the fact that a single dextramer carries multiple
fluorochrome molecules. The greater pMHC valency and
scaffold flexibility of dextramers compared to tetramers
could also increase the cell surface interaction avidity,
potentially leading to higher molecular occupancy. Subse-
quent experiments were performed using the optimal stain-
ing conditions for each reagent.
pMHC-I dextramers exhibit superior fluorescence
compared with pMHC-I tetramers
We next set out to compare how pMHC tetramers and
dextramers stained T cells over a range of predefined TCR–
pMHC affinities. To this end, we again made use of the
ILA1 CD8+ T cell clone, as this clone has the widest range of
biophysically characterized agonist ligands described thus
far (KD ∼3 μM to ∼2 mM). Optimized staining of the CD8+
ILA1 clone showed that pMHC dextramers gave consider-
ably brighter staining than achieved with pMHC tetramers
(Fig. 1b). This difference was most noticeable when the
TCR–pMHC interaction was exceptionally weak. The MFI
of staining with multimers composed of the 5Y peptide
(KD < 250 μM) was more than 75-fold brighter with
dextramer than with tetramer (Fig. 1b). pMHC multimers
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are often used to detect antigen-specific T cells in ex vivo
samples. In order to mimic this situation in a controlled
setting, 106 HLA-A2+ PBMC were spiked with 104 ILA1 T
cell clone prior to staining (1%). Optimal staining of ILA1
cells with dextramer was substantially brighter in all cases
than with the corresponding tetramer (Fig. 1c). This differ-
ence became increasingly noticeable when TCR–pMHC
interactions were weak, to a point where cells could be suffi-
ciently detected with dextramer of the 5Y variant
(KD > 250 μM), but not the corresponding tetramer. Addi-
tionally, the admixed ILA1 cells could be detected with
dextramer of the 8E variant [KD > 500 μM, and we believe
close to 2 mM by extrapolation of response units from
surface plasmon resonance (SPR) binding experiments],
but not at all with the corresponding tetramer.
pMHC-II dextramers exhibit improved staining over
pMHC-II tetramers
The CD8 co-receptor binds to largely invariant parts of
MHC-I and acts to ‘co-receive’ the pMHC-I ligand with the
TCR [27,28]. The CD4 co-receptor performs a similar role
for pMHC-II ligands [29]. The CD8 co-receptor binds to
MHC-I with an affinity KD ∼100–200 μM [30,31], and acts
to enhance the on-rate and slow the off-rate of the TCR–
pMHC-I interaction at the cell surface [1,32]. The combi-
nation of avidities arising from TCR–pMHC-I and pMHC-
I–CD8 interactions can substantially impact upon pMHC
tetramer staining [6,9,13,15,33]. In contrast, pMHC-II–
CD4 binding is too weak to be measured by techniques such
as SPR [1,32]. The current consensus is that the CD4
co-receptor does not play a leading role in stabilizing the
TCR–pMHC-II interaction and thus in the binding of
pMHC-II tetramers [1,8,34,35]. This lack of CD4 ‘co-
receptor help’ combined with a weaker TCR interaction
ensures that it is considerably more difficult to stain the
average CD4+ T cell with pMHC multimer than it is to stain
the average CD8+ T cell [1]. Indeed, it is well established
that CD4+ T cells are notoriously difficult to detect using
pMHC tetramer technology [1,8,16].
To determine whether the staining advantage of pMHC-I
dextramers over tetramers was also true for the pMHC-II
system, we used a CD4+ T cell clone (Flu2C5), specific for
the HLA-DR1-restricted epitope PKYVKQNTLKLAT (resi-
dues 307–319) from HA of influenza virus A. Staining of
the Flu2C5 clone with pMHC-II dextramer was more than
fivefold brighter than with the corresponding tetramer
(Fig. 2a). To examine staining performance in a setting
analogous to the ex vivo situation, we spiked HLA-DR1+
PBMCs with Flu2C5 cells at a frequency of 1%. Of note, the
Flu2C5 clone was easily distinguishable in these experi-
ments as a consequence of exceptionally high CD4 expres-
sion (Fig. 2b). Again, the cognate pMHC-II dextramer
stained Flu2C5 cells readily with sensitivity and specificity,
in contrast to the corresponding tetramer (Fig. 2b).
pMHC dextramers allow high-definition detection of
autoimmune T cells
Autoimmune TCR–pMHC interactions are characterized by
poor in vivo molecular association between the autoim-
mune epitope and the MHC or by a weak TCR–pMHC
interaction [7,22]. Both scenarios can create a serious
problem for pMHC multimer staining, as the result of
either poor pMHC stability or TCR–pMHC interactions
that fall below the threshold for pMHC tetramer staining.
In order to examine staining of autoimmune T cells we used
a clone specific for the HLA-A2-restricted, PPI-derived
epitope, ALWGPDPAAA (residues 15–24). The 3F2 clone
was derived from a patient with T1D and is known to bear
an identical TCR to the 1E6 and PEAK1 T cell clones grown
from the same patient at different time-points [23]. This
TCR binds to HLA-A2–ALWGPDPAAA with a
KD > 250 μM [36]. Staining of the 3F2 clone with pMHC
dextramer was much greater than 20-fold brighter than
could be achieved with pMHC tetramer made with identi-
cal pMHC (Fig. 3a). In turn, this enhanced staining allowed
clear distinction of these antigen-specific cells when they
were spiked into HLA-A2+ PBMC at 1% of total cells
(Fig. 3b). We thus conclude that pMHC dextramers can be
superior to the corresponding tetramers for the detection of
autoimmune T cells.
Dextramers exhibit superior identification of
antigen-specific T cells ex vivo
pMHC multimers are generally used for the detection of T
cells in ex vivo samples. We next compared how pMHC-I
tetramers and dextramers performed in this setting. The
affinity of TCR–pMHC interactions tends to exhibit a hier-
archy whereby anti-pathogen > anti-self (tumour) > auto-
immune [7,37]. In order to study each of these categories,
we stained HLA-A2+ samples from non-T1D and T1D indi-
viduals with reagents specific for the epitopes:
GLCTLVAML from BMLF-1 (residues 259–267) of Epstein–
Barr virus (EBV); ELAGIGILTV of MART-1 (residues
26–35: heteroclitic amino acid shown in bold [36]); and
ALWGPDPAAA of PPI (residues 15–24). HLA-A2-
GLCTLVAML dextramer stained an identical proportion of
cells to tetramer in two of three samples and slightly more
cells in a third sample (1·57% compared to 1·45% of CD8+
T cells for dextramer and tetramer, respectively) (Fig. 4).
The MFI of staining with dextramers was considerably
higher (2·70–5·75 fold increase) in all cases. In con-
trast, dextramers constructed with HLA-A2-ELAGIGILTV
stained almost twice as many cells as the corresponding
tetramer (Fig. 4). This difference became even more pro-
nounced when paired HLA-A2-ALWGPDPAAA reagents
were used to stain PBMC samples from patients with T1D
(Fig. 4 and Supporting Information Fig. S2). Overall, for all
the specificities studied in the ex vivo setting, the
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dextramers stained significantly brighter (P ≤ 0·01: paired,
two-tailed t-test) and detected significantly more antigen-
specific T cells (P ≤ 0·01: paired, two-tailed t-test) than
tetramers.
pMHC dextramer staining is enhanced by
PKI treatment
We have recently described how pMHC staining in the pres-
ence of PKI can substantially improve staining with pMHC
multimers [1,19]. We next sought to determine whether
these improvements extended to pMHC dextramers,
thereby increasing the range of specific interactions that
could be detected. To this end, we stained the ILA1 T cell
clone that had been preincubated with or without 50 nM
dasatinib for 30 min as indicated (Fig. 5). The MFI of both
pMHC tetramer and dextramer staining increased when
cells were preincubated with dasatinib in all cases. This dif-
ference was most noticeable when the TCR–pMHC affinity
decreased, with a maximal effect observed with the 5Y
ligand, where PKI treatment increased the MFI by almost
4·5-fold. These results indicate that a combination of
pMHC dextramer and 50 nM dasatinib allowed detection
of cognate T cells by pMHC multimers with the weakest
TCR affinity. Indeed, this combination gave good staining
even with the 5Y variant (KD > 250 μM). We next examined
the use of pMHC tetramers and dextramers for distinction
of T cells within PBMC samples. Figure 6 shows that
pMHC dextramer + 50 nM dasatinib enabled better recov-
ery of ILA1 clone spiked into HLA-A2 PBMC when
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Fig. 2. Dextramers made with peptide–major
histocompatibility complex (pMHC) class II
bind CD4+ T cells substantially better than
tetramers. (a) The influenza (Flu)2C5 CD4+ T
cell clone was stained with phycoerythrin
(PE)-conjugated (right) or dextramer (left)
reagents constructed with human leucocyte
antigen (HLA)-DR1 monomers bearing the
cognate influenza A virus HA307–319 peptide
(PKYVKQNTLKLAT; red line) or the HIV-1
p24 Gag299–312 peptide (DRFYKTLRAEQASQ;
green line) as an irrelevant control. Mean
fluorescence intensity (MFI) values are shown
inset for each tetramer/dextramer reagent and
unstained cells (black line). (b) Human
peripheral blood mononuclear cells (PBMCs)
(106) were spiked with clonal Flu2C5 cells (104)
and stained with the indicated tetramers (right)
or dextramers (left), the viability dye Aqua and
monoclonal antibodies against the surface
markers CD3, CD4, CD8, CD14 and CD19.
Gates were set serially on lymphocytes, single
cells and live CD3+CD14−CD19− cells prior to
display as CD4 versus tetramer/dextramer. MFI
values are shown inset.
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Fig. 3. Dextramers bind a type I diabetes-derived CD8+ T cell clone substantially better than tetramers and also distinguish such cells from other T
cells in a spiked peripheral blood mononuclear cell (PBMC) setting. (a) The 3F2 CD8+ T cell clone was stained with phycoerythrin (PE)-conjugated
tetramer (right) or dextramer (left) reagents constructed with human leucocyte antigen (HLA)-A2 monomers bearing the cognate preproinsulin
(PPI)15–24 peptide (ALWGPDPAAA) or the melanoma antigen (MAGE) A3168–176 peptide (YLEYRQVPV) as an irrelevant control. Different amounts
of tetramer or dextramer were used as indicated with respect to the monomeric peptide-major histocompatibility complex (pMHC) component.
Mean fluorescence intensity (MFI) values are shown for each condition. (b) Human PBMCs (106) were spiked with clonal 3F2 cells (104) and stained
with the indicated tetramers (right) or dextramers (left), the viability dye Aqua and monoclonal antibodies against the surface markers CD3, CD4,
CD8, CD14 and CD19. Gates were set serially on lymphocytes, single cells and live CD3+CD14−CD19− cells prior to display as CD8 versus
tetramer/dextramer. Clonal 3F2 cells were easily distinguishable on the basis of brighter CD8 expression. Reagent quantities with respect to the
pMHC-I component (black) and MFI values (red) are shown inset.
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Fig. 4. Superior ex vivo detection of antigen-
specific CD8+ T cells with dextramers. Human
leucocyte antigen (HLA)-A2+ peripheral blood
mononuclear cells (PBMCs) from non-type I
diabetes (T1D) donors (left, middle) or T1D
patients (right) were stained with tetramer or
dextramer reagents constructed with HLA-A2
monomers bearing the Epstein–Barr virus (EBV)
BMLF-1259–267 peptide (GLCTLVAML; left), the
MART-126–35 heteroclitic peptide (ELAGIGILTV;
middle) or the preproinsulin (PPI)15–24 peptide
(ALWGPDPAAA; right). Each symbol and line
combination denotes a different donor. Gates
were set serially on lymphocytes, single cells and
live CD3+CD14−CD19− cells prior to analysis as
CD8 versus tetramer/dextramer. Detected
antigen-specific CD8+ T cell frequencies (top)
and mean fluorescence intensity (MFI) values
(bottom) are shown. Representative flow
cytometry plots are shown in Supporting
Information Fig. S2. The difference in MFI and
percentage of CD8+ T cells detected between
dextramers and tetramers is significantly
different (P ≤ 0·01: paired, two-tailed t-test).
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Fig. 5. Peptide–major histocompatibility
complex (pMHC) dextramer staining is
enhanced by protein kinase inhibitor (PKI)
treatment. The ILA1 CD8+ T cell clone was
stained with phycoerythrin (PE)-conjugated
tetramer (right) or dextramer (left) reagents
constructed with human leucocyte antigen
(HLA)-A2+ monomers bearing the cognate
human telomerase reverse transcriptase
(hTERT)540–548 peptide (ILAKFLHWL), variants
thereof with defined T cell receptor
(TCR)-pMHC-I affinities as indicated in the
key, or the HIV-1 Pol476–484 peptide
(ILKEPVHGV) as an irrelevant control after
pretreatment with (bottom) or without (top)
50 nM dasatinib. Mean fluorescence intensity
(MFI) values are shown inset.
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compared to dextramer alone or tetramer ± 50 nM
dasatinib. Indeed, for the weak 4L and 5Y ligands
(KD = 117 μM and > 250 μM, respectively) a hierarchy of
cell recovery emerged of dextramer + PKI > dextramer >
tetramer + PKI > tetramer. pMHC tetramer of the 5Y
variant alone failed to distinguish an ILA1 population. Con-
versely, pMHC dextramer of the 8E variant that we believe
to have a KD of ∼2 mM was capable of low-level staining in
the presence of 50 nM dasatinib.
It is noticeable in Fig. 5 that the dextramer made with the
5Y variant caused some non-specific increase in fluores-
cence of some CD8high T cells compared to the other rea-
gents or staining with tetramer made with identical pMHC.
We have observed this effect with only some pMHC mono-
mers. We do not know the reason for this background, as it
only ever occurs with PBMC from a minority of individu-
als. This effect also occurs in Fig. 3.
In further experiments, we studied two autoimmune
CD8+ T cell clones isolated from patients with T1D. These
clones kill human pancreatic β cells in a pMHC-I-specific
manner [23,24], and bind their respective cognate antigens
weakly (4C6, KD = 100 μM; 1E6, KD = 256 μM). In both
cases, optimal staining was again observed with the
dextramer/dasatinib combination (Fig. 7).
To expand these observations to the ex vivo setting, we
took advantage of the fact that there can be substantial
populations of naive CD8+ T cells specific for the HLA-A2-
restricted MART-126–35 peptide in the blood of healthy
individuals [38]. The size of this unique antigen-specific
precursor pool appears to reflect epitope recognition
by germline-encoded TCR residues [39]. In HLA-A2+
PBMCs, clear populations CD8+ T cells specific for the
heteroclitic ELAGIGILTV peptide were detected directly ex
vivo with the cognate pMHC-I tetramer (Fig. 8). Greater
numbers of cells were revealed after PKI treatment and the
dextramer/dasatinib combination was again optimal, both
in terms of population magnitude and staining intensity
(Fig. 8).
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Fig. 6. Superior recovery of antigen-specific CD8+ T cells with peptide–major histocompatibility complex (pMHC) dextramer + protein kinase
inhibitor (PKI). Human peripheral blood mononuclear cells (PBMCs) (106) were spiked with clonal ILA1 cells (104), pretreated with or without
50 nM dasatinib (+/− PKI) and then stained with phycoerythrin (PE)-conjugated tetramer (lower) or dextramer (upper) reagents as indicated
(details in Fig. 5), followed by the viability dye Aqua and monoclonal antibodies against the surface markers CD3, CD4, CD8, CD14 and CD19.
Gates were set serially on lymphocytes, single cells and live CD3+CD14−CD19− cells prior to display as CD8 versus tetramer/dextramer. In each
column, the red box is positioned on the antigen-specific CD8+ T cell population that stains most brightly to aid visual comparison.
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pMHC dextramers are compatible with high-resolution
flow cytometry
Polychromatic flow cytometry is used frequently in conjunc-
tion with pMHC multimers to characterize antigen-specific
T cells directly ex vivo. As dextramers are substantially bigger
than tetramers, it is feasible that they could sterically hinder
subsequent staining with fluorescent antibodies. To test this
possibility, we stained HLA-A2+ PBMCs with reagents spe-
cific for the CMV epitope NLVPMVATV (pp65: residues
495–503) followed by a panel of monoclonal antibodies spe-
cific for various surface activation and differentiation
markers (Fig. 9). The phenotypical data were similar regard-
less of whether tetramers or dextramers were used to identify
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with human leucocyte antigen (HLA)-A24 monomers bearing the LWMRLLPLL peptide or HLA-A2 monomers bearing the ALWGPDPAAA
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Fig. 8. Superior ex vivo detection of
antigen-specific CD8+ T cells with a
combinatorial staining approach using a protein
kinase inhibitor (PKI) and peptide–major
histocompatibility complex (pMHC) dextramer.
Human leucocyte antigen (HLA)-A2+ peripheral
blood mononuclear cells (PBMCs) from healthy
controls were stained with phycoerythrin
(PE)-conjugated tetramer (right) or dextramer
(left) reagents constructed with HLA-A2
monomers bearing the MART-126–35 heteroclitic
peptide (ELAGIGILTV) after pretreatment with
or without 50 nM dasatinib (+/− PKI). Gates
were set serially on lymphocytes, single cells and
live CD3+CD14−CD19− cells prior to display as
CD8 versus tetramer/dextramer. Detected
antigen-specific CD8+ T cell frequencies (black)
and mean fluorescence intensity (MFI) values
(red) are shown inset.
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the antigen-specific CD8+ T cell population. Of note, the
enhanced brightness of dextramer-stained cells in the PE
channel necessitated minor compensation adjustments
(PECy7). Bright compensation controls are therefore advis-
able for dextramer reagents.
pMHC dextramers are compatible with intracellular
cytokine staining
pMHC multimers allow the physical staining of antigen-
specific T cells by flow cytometry. Flow cytometry can also
be used to separate T cells based on functional activation
markers such as CD69 or CD107 that appear transiently on
the cell surface after exposure to cognate antigen. Alterna-
tively, antigen-specific T cells can be stained for the accu-
mulation of cytokines in the endoplasmic reticulum after
antigenic stimulation (intracellular cytokine staining; ICS).
As ICS involves TCR stimulation and concomitant TCR
triggering and down-regulation, it results in a lower TCR
density at the T cell surface. During the manuscript review
process, we were asked whether dextramer staining was
compatible with ICS and whether the increased pMHC and
fluorochrome payload of pMHC dextramers compared to
pMHC tetramers might result in improved staining follow-
ing ICS. In order to compare the performance of pMHC
dextramers and tetramers in conjunction with ICS we used
a 10-day-old T cell line primed from a HLA-A2 individual
using the influenza epitope, GILGFVFTL (matrix protein
residues 58–66). Influenza matrix-specific cells could be
detected in this line by flow cytometry using cognate
pMHC dextramer and tetramer or by ICS for IFN-γ
(Fig. 10a–c). The IFN-γ-positive cells shown in the red gate
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Fig. 9. Peptide–major histocompatibility complex (pMHC) dextramers are compatible with high-resolution flow cytometry. Human leucocyte
antigen (HLA)-A2+ peripheral blood mononuclear cells (PBMCs) from healthy controls were stained with phycoerythrin (PE)-conjugated or
dextramer reagents constructed with HLA-A2 monomers bearing the CMV pp65495–503 peptide (NLVPMVATV), followed by the viability dye ViViD
and monoclonal antibodies against the surface markers CD3, CD8, CD14, CD19, CD27, CD45RO, CD57, CD69 and CCR7. Gates were set serially on
lymphocytes, single cells and live CD3+CD14−CD19− cells (a) prior to display as CD8 versus tetramer/dextramer (b,c). Boolean gating was carried out
to exclude artefacts and fluorochrome aggregates as indicated (a). Yellow or green dots superimposed on density plots showing the phenotypical
profile of the overall CD8+ T cell population depict individual antigen-specific CD8+ T cells stained with dextramer or tetramer, respectively (d–i).
The following bivariate analyses are shown: CD27 versus CD45RO (d,e); CD57 versus CCR7 (f,g); and CD69 versus CCR7 (h,i).
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of Fig. 10c were co-stained with cognate and irrelevant
(ALWGPDPAAA: residues 15–24 from PPI) pMHC
dextramer and tetramer. Almost all these cells (94%) could
be detected with HLA-A2-GILGFVFTL dextramer com-
pared to just 32% recovery with pMHC tetramer made at
the same time using the same monomer. We conclude that
pMHC dextramers are compatible with ICS and that these
reagents are better at recovering antigen-specific cells post-
activation than corresponding pMHC tetramers.
pMHC dextramers are rapidly internalized by
cognate T cells
pMHC tetramers are rapidly internalized by antigen-
specific T cells [40], ensuring that they can be captured
from solution swiftly and irreversibly. We examined staining
of NLV2F3 T cells with HLA-A2–NLVPMVATV tetramer
and dextramer. Both reagents were rapidly internalized at
37°C (Fig. 11). This internalization was largely inhibited
when cells were stained on ice and completely inhibited in
the presence of 50 nM dasatinib at 37°C. These experiments
confirm that the PKI, dasatinib, prevents internalization of
TCRs (and pMHC multimer) during staining and show that
tetramer and dextramer staining patterns are very similar
despite the greater brightness with dextramer multimers.
Discussion
In this study we conducted parallel comparative analyses of
optimized T cell staining with pMHC tetramers and new
dextramer technology assembled with the same pMHC
monomer. pMHC tetramers performed well when the
monomeric TCR–pMHC affinity was relatively high
(KD < 20 μM). TCR interactions of this strength are typical
of CD8+ T cells that respond to pathogen-derived peptides
[7] and pMHC tetramers have excelled for such applica-
tions. Our own studies have established that the binding
affinity threshold for pMHC-I tetramers is higher than that
required for T cell activation [6]. As a result, standard
pMHC tetramer staining fails to detect all the T cells that
are capable of responding to a particular antigen, as T cells
with weak, but functional, TCRs might not be detected.
This issue becomes especially relevant when using pMHC
tetramers to detect T cells that recognize self-derived
peptides (tumour-specific and autoimmune T cells) or
MHC-II-restricted T cells, as such cells bear TCRs that bind
with relatively low affinity [7].
For comprehensive assessment we first made use of the
human HLA-A2-restricted T cell clone ILA1, as there is a
wide range of characterized analogue ligands for the ILA1
TCR that bind with logarithmically divergent affinities (KD
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Fig. 10. Dextramers can be used to detect
activated T cells during an intracellular cytokine
assay. A 10-day-old enriched T cell line specific
for the influenza epitope, GILGFVFTL (matrix
protein residues 58–66), was cultured with or
without cognate peptide for 5 h in the presence
of monensin and brefeldin A. Cells were
subsequently stained with cognate [human
leucocyte antigen (HLA)-A2 GILGFVFTL] or
irrelevant (HLA-A2–ALWGPDPAAA)
dextramer or tetramer, cell surface markers
(CD8, CD3, CD19, CD14), a viability stain and
intracellularly for interferon (IFN)-γ.
Unstimulated cells were stained with cognate
dextramer (a) or tetramer (b), with the gate
shown based on staining with an irrelevant
dextramer or tetramer. The percentage of
staining of IFN-γ+ cells (c: red gate, based on a
fluorescence minus 1) with cognate dextramer
(red) or tetramer (green) is based upon the
staining of the same IFN-γ+ cells with an
irrelevant dextramer (blue) or tetramer
(orange) (d). The percentage of gated cells
shown inset (a–c).
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from 3 μM to ∼2 mM). Importantly, all analogues bind to
the HLA-A2 molecule with identical affinities [6]. The ILA1
T cell clone stained well with both the 3G and wild-type
ILA1 ligand (KD 3 μM and 32 μM, respectively), but became
increasingly poor with weaker ligands. Parallel staining of
ILA1 cells with the corresponding pMHC dextramer gave
brighter fluorescence intensity than pMHC tetramer in all
cases. This difference became most noticeable with the 4L
and 5Y variants that bind with affinities of KD 117 μM and
approximately 250 μM, respectively. This difference in
staining was manifest when the ILA1 clone was spiked into
HLA-A2+ PBMC to mimic the conditions of direct ex vivo
staining allowing a clean detection of the antigen-specific
population from the background PBMC with dextramers
when TCR–pMHC affinity was low. Given these observa-
tions, we conclude that pMHC dextramers perform signifi-
cantly better than pMHC tetramers for T cell detection
when TCR–pMHC affinity is low.
Weak TCR affinities are characteristic of T cells specific
for self-derived peptides (tumour-specific and autoimmune
T cells) and MHC-II-restricted T cells [7]. Given this, we
next performed comparisons of pMHC tetramer and
pMHC dextramer with MHC-II-restricted T cells and auto-
immune T cells in order to test whether dextramers would
be better at identifying this subset of antigen-specific T
cells. Optimal staining of an HLA-DR1-restricted CD4+ T
cell clone (Flu2C5) specific for an influenza-derived peptide
with pMHC dextramer was more than five times brighter
than with the equivalent pMHC tetramer. Increased stain-
ing MFI of Flu2C5 with pMHC dextramer compared to
tetramer allowed this clone to be clearly distinguishable
when it was spiked into HLA-DR1+ PBMC. pMHC
dextramers stained the autoimmune T cell clone 3F2, which
expresses the 1E6 TCR [22,23], with more than 17 times
higher intensity than the equivalent pMHC tetramer, allow-
ing clear distinction of these cells from a HLA-A2+ PBMC
sample. Taken together, these experiments indicate that
pMHC dextramers afford considerable advantages over
pMHC tetramers for T cell staining. This advantage is par-
ticularly distinct when TCR–pMHC affinity is low, allowing
detection of MHC-II-restricted and autoimmune T cells.
We next set out to compare pMHC dextramers to
tetramers under the conditions that these reagents are often
used for the detection of antigen-specific T cells in ex vivo
samples. We chose to examine staining for T cells specific
for viral, tumour and autoimmune antigens in the context
of HLA-A2, as the TCRs that bind to such antigens tend to
vary in affinity [7]. Dextramers and tetramers stained
similar numbers of EBV-specific T cells, although staining
with dextramers was brighter. Dextramers of a MART-1-
derived peptide stained greater numbers of cells than
equivalent tetramers. This difference was most exaggerated
when pMHC multimers of a PPI-derived peptide were used
to stain T cells in the blood of T1D patients. Collectively,
these data show that pMHC dextramers outperform pMHC
tetramers in identifying antigen-specific T cells ex vivo.
We have recently described how the PKI dasatinib can aid
staining with pMHC tetramers by preventing down-
regulation of the TCR from the T cell surface [19]. This
inexpensive and easily applied ‘trick’ is especially useful
I
Fig. 11. Similar visual staining patterns with peptide–major histocompatibility complex (pMHC) dextramers and tetramers. The NLV2F3 CD8+ T
cell clone was stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue), followed by Alexa488-conjugated tetramer or fluorescein isothiocyanate
(FITC)-conjugated dextramer reagents constructed with human leucocyte antigen (HLA)-A2 monomers bearing the cytomeglovirus (CMV)
pp65495–503 peptide (NLVPMVATV). Staining conditions are indicated; dasatinib was used at a concentration of 50 nM. Cells were visualized using a
Leica DM LB2 fluorescent microscope.
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when staining T cells with low-affinity TCRs, such as those
that predominate in tumour-specific and autoimmune T
cell populations. For competitive assessment of this reagent,
four PKI staining conditions were applied to the model
ILA1 T cell clone: tetramer ± PKI and dextramer ± PKI.
A clear hierarchy of staining intensity was observed, of
the order dextramer + PKI > dextramer > tetramer + PKI >
tetramer. Staining with dextramer + PKI was 14·6 and 29·4-
fold more intense than optimal staining with tetramer with
the 4L and 5Y ligands, respectively. We conclude that the
highest intensity of staining is seen by using pMHC
dextramers in conjunction with PKI. Staining with
dextramer + PKI also gave the best distinction of ILA1 cells
spiked into HLA-A2+ PBMC. Of significant note is that we
even observed staining with the 8E variant under these con-
ditions. We estimate that the ILA1 TCR binds to this ana-
logue with a KD of ∼2 mM. Dextramer + PKI also gave the
highest staining intensity of HLA-A2 and HLA-A24 CD8+ T
cell clones isolated from the blood of patients with T1D and
specific for preproinsulin-derived peptides. We next took
advantage of the fact that there are relatively large popula-
tions of naive T cells in HLA-A2+ individuals that are spe-
cific for the melanoma-derived self-peptide ELAGIGILTV
[38]. Staining of HLA-A2+ PBMC directly ex vivo with the
four conditions described above showed that the number of
cells detected also increased in the order of dextramer +
PKI > dextramer > tetramer + PKI > tetramer. We conclude
that a combination of dextramer and PKI yields optimal
cell identification when targeting T cells that are specific for
self-derived peptides.
pMHC tetramers are often utilized in conjunction with
fluorochrome-conjugated antibodies for T cell phenoty-
ping. Dextramers are built around a dextran backbone and
have considerably larger atomic mass compared with
pMHC tetramers. This raised concerns that dextramers
might induce steric hindrance against other detection
agents when attached to the cell surface and/or alter T cell
phenotyping. We tested this concern by phenotyping
tetramer- and dextramer-isolated CMV-specific CD8+ T
cells directly ex vivo with a marker for viability and directly
conjugated antibodies specific for the surface markers CD3,
CD8, CD14, CD19, CD27 CD57, CD45R0, CD27, CD57,
CD69 and CCR7 (Fig. 9). Both reagents performed simi-
larly, although once again the dextramer gave much
brighter staining than the corresponding tetramer. The
enhanced staining observed with pMHC dextramers sug-
gests that it may be possible to utilize these reagents in con-
junction with less bright fluorochromes, thereby saving the
brightest fluorochromes for the staining of cellular markers
with low abundance. Thus, pMHC dextramers might allow
cellular phenotyping that would not be routinely possible
with pMHC tetramers. Further work will be required in
order to formally demonstrate this advantage.
Antigen-specific T cells are often sorted following anti-
genic stimulation and intracellular cytokine staining. This
process involves TCR triggering and down-regulation of
TCRs from the cell surface and can result in reduced stain-
ing with pMHC tetramers. Direct comparative staining of
IFN-γ-positive cells with pMHC dextramers and tetramers
following antigenic stimulation of an influenza matrix-
specific T cell line showed that pMHC dextramers were able
to stain the vast majority of IFN-γ-positive cells. In contrast,
fewer than a third of antigen-specific cells by IFN-γ staining
could be co-stained with cognate pMHC tetramer. We con-
clude that recovery of stimulated cells with pMHC
dextramer is more efficient than with the corresponding
tetramer reagent. This improvement in recovery might be
particularly important when using pMHC multimers to
confirm the specificity of T cells that activate in ICS assays
upon exposure to a specific pathogen, self or cancer target.
Our final aim was to visualize in real time T cells that had
been stained under different conditions using both
tetramers and dextramers. These studies confirmed our pre-
vious findings [40], showing that tetramers are rapidly
internalized by antigen-specific T cells at physiological tem-
perature (37°C). The distribution of staining with tetramer
and dextramer was similar. Internalization of both tetramer
and dextramer was largely inhibited when cells were stained
on ice. The pattern of staining with tetramers and
dextramers at 37°C + 50 nM dasatinib confirmed that this
PKI prevents the internalization of pMHC multimers. Thus,
both pMHC tetramers and pMHC dextramers stain cells
similarly.
In summary, we rigorously compared pMHC-I and
pMHC-II tetramers and dextramers for staining a range of
T cells. Both reagents performed well when the TCR affinity
was high (e.g. anti-viral CD8+ T cells), although the higher
valency reagent always stained with higher intensity. This
difference in staining intensity became especially noticeable
when TCR affinity was low. As we have reported previously,
pMHC tetramers struggle to stain T cells where the TCR
affinity is lower than KD ∼80 μM [6]. Unfortunately, the
threshold for T cell activation can be much weaker than
this, such that pMHC tetramers sometimes fail to detect T
cells capable of responding to the multimerized ligand. This
issue is especially problematic when staining T cells that
have low-affinity TCRs such as tumour-specific T cells,
autoimmune T cells and MHC-II-restricted T cells. Here,
we show that the greater pMHC density and fluorochrome
load carried by pMHC dextramers circumvents this
problem to allow staining of these important T cell popula-
tions. Importantly, pMHC dextramers performed well when
used for multiplex, polychromatic, T cell phenotyping and
in conjunction with ICS. As pMHC dextramers stain T cells
much more effectively than the equivalent tetramer, we
believe that they could be used with less bright
fluorochromes, thereby saving the brightest fluorochomes
for staining low-abundance molecules at the T cell surface.
In conclusion, our study serves to further highlight that
pMHC tetramers fail to stain T cells in cases where the
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TCR–pMHC interaction is low. As such interactions can
still initiate T cell activation [6], this means that pMHC
tetramers can fail to identify all T cells that respond to a
particular pMHC. The use of pMHC dextramers in con-
junction with 50 nM dasatinib allows robust staining of T
cells even when the TCR–pMHC affinity is weak
(KD > 250 μM), thus enabling ready detection of tumour-
specific and autoimmune T cells that might be missed when
using pMHC tetramers.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1. Establishing an optimal amount of peptide–major
histocompatibility complex (pMHC) dextramer and tetra-
mer to use per test when staining a T cell clone. The ILA1
CD8+ T cell clone was stained with different quantities of
phycoerythrin (PE)-conjugated tetramer or dextramer rea-
gents constructed with human leucocyte antigen (HLA)-A2
monomers bearing the cognate human telomerase reverse
transcriptase (hTERT)540–548 peptide (ILAKFLHWL) (a,c) or
the HIV-1 Pol476–484 peptide (ILKEPVHGV) as an irrelevant
control (b,d). Optimal titres with respect to the pMHC-I
component (red) were set at the highest signal-to-noise ratio
established by comparison of wild-type to irrelevant rea-
gents. Unstained (fluorescence minus one; FMO) controls are
shown.
Fig. S2. Enhanced ex vivo detection of antigen-specific
CD8+ T cells with dextramers. Dextramers and tetramers
were assembled using the same batch of human leucocyte
antigen (HLA)-A2 monomer containing epitopes from the
BMLF-1259–267 protein of Epstein–Barr virus (EBV)
(GLCTLVAML) (a), MART-126–35 (ELAGIGILTV; hetero-
clitic amino acid shown in bold) (b) and preproinsulin
(PPI)15–24 (ALWGPDPAAA) (c). Dextramers and tetramers
containing the PPI epitope were used to stain peripheral
blood mononuclear cells (PBMC) directly ex vivo from
HLA-A2+ patients with type 1 diabetes (T1Ds) (c), whereas
all other PBMC was sourced from HLA-A2+ non-TID
donors (a,b). The percentage of dextramer or tetramer-
positive cells of CD8+ T cells and the mean fluorescence
intensity (MFI) of this population is displayed in bold. The
gates were set on: 1, lymphocytes; 2, single cells; 3, amine-
CD3+CD14–CD19– cells. The subsequent gate was set on
CD8 versus dextramer and tetramer and events displayed
using large dots.
Fig. S3. High-resolution version of Fig. 1a.
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